Following 6.3% Q1 Sales Slump, Herbalife Expects To Ride North America To Turnaround
Executive Summary
Direct seller declines to provide guidance due to dynamic macroeconomic environment but expects a return to growth by end of year led by North America.
You may also be interested in...
US Nutritionals Market Q3 Results: Herbalife, Abbott, ChromaDex, USANA, Mannatech
Herbalife’s five sales regions leaving behind pandemic impact at different speeds; Abbott’s 15.5% nutritional sales growth didn’t overcome more than 30% slump in diagnostics sales; ChromaDex steady sales growth for most of past three years continues with 14% in latest quarter; USANA and Mannatech results slump.
US Q2 Consumer Health Earnings Preview: Two Firsts On Table For Perrigo, One For Kenvue
Perrigo will note regulatory approval for Opill as first US OTC oral contraceptive in first earnings briefing with Patrick Lockwood-Taylor at helm. Other firsts in sector will be Kenvue’s 20 July results being its first since spin-out from J&J in May and Bausch + Lomb’s first quarterly results under CEO Saunders.
Herbalife Relaunches To ‘2.0’ With 'Unified, Global Platform' After Sales Fall 10.3% In 2022
Direct seller announces relaunch after year-long sales slump blamed on macroeconomic inflationary pressures. No full-year guidance due to rapidly shifting macroeconomic environment and increased market volatility.